Legend Biotech’s stock has seen a significant surge due to promising off-the-shelf in vivo CAR-T results, prompting increased interest from potential acquirers like Johnson & Johnson. The company is exploring opportunities to expand its technology into autoimmune treatments, while also addressing regulatory challenges in cell therapy production. Insider trading activity includes a recent sale of shares by CEO Ying Huang, and hedge fund activity shows notable interest from institutional investors. Analysts have issued positive ratings with a median price target of $64.5 for the stock.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.quiverquant.com/news/Legend+Biotech+Stock+%28LEGN%29+Opinions+on+In+Vivo+CAR-T+Results
